LENSAR

LENSAR EBITDA per Share

The EBITDA per Share of LENSAR (LNSR) as of Oct 16, 2026 is -2.04 USD. In the previous year, EBITDA per Share was -0.83 USD — a change of 144.19% (lower).

EBITDA per Share

-2.04USD

YoY

144.19%

Last updated:

EBITDA per Share of LENSAR is 2025 -2.04 USD. EBITDA per Share of LENSAR was 2024 -0.83 USD. It decreases by 144.19% lower compared to the previous year.

The LENSAR EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-8.18 USD
Jan 1, 2019
-1.07 USD
Jan 1, 2020
-1.95 USD
Jan 1, 2021
-1.93 USD
Jan 1, 2022
-1.84 USD
Jan 1, 2023
-0.99 USD
Jan 1, 2024
-0.83 USD
Jan 1, 2025
-2.04 USD
The LENSAR EBITDA per Share history
YEAREBITDA per ShareYoY
-2.04USD+144.19%
-0.83USD-15.84%
-0.99USD-46.04%
-1.84USD-4.69%
-1.93USD-1.45%
-1.95USD+81.91%
-1.07USD-86.86%
-8.18USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LENSAR Stock analysis

What does LENSAR do? LENSAR Inc is a healthcare company based in Orlando, Florida, specializing in femtosecond laser technology for refractive cataract surgery. The company went public on September 21, 2020, and currently employs 150 full-time employees. LENSAR develops and markets femtosecond laser systems designed to treat cataracts and manage pre-existing or surgically induced corneal astigmatism. Its primary products include the LENSAR Laser System, which features Streamline IV and IntelliAxis technologies, along with associated consumable components such as a disposable patient interface device kit. The company also offers the ALLY Adaptive Cataract Treatment System, a compact device integrating femtosecond laser capabilities with enhanced laser features for single-room cataract procedures. LENSAR's technology aims to assist surgeons in achieving optimal visual outcomes during cataract surgery. The company operates within the healthcare sector, focusing on innovative solutions for ophthalmic procedures. Its headquarters in Orlando serves as the central hub for research, development, and business operations. LENSAR's website, lensar.com, provides further details about its products and services. The firm's product portfolio emphasizes precision and efficiency in surgical treatments, targeting healthcare providers seeking advanced tools for cataract management. As a publicly traded entity under the ticker LNSR, LENSAR continues to advance its technological offerings in the medical device industry. LENSAR is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LENSAR stock

EBITDA per Share of LENSAR is -2.04 USD in 2025.

EBITDA per Share of LENSAR changed from -0.83 USD to -2.04 USD, representing a 144.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share LENSAR since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — LENSAR

All Key Metrics — LENSAR